SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-095173
Filing Date
2024-11-07
Accepted
2024-11-07 07:30:40
Documents
73
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0220052-10q_jasper.htm   iXBRL 10-Q 895766
2 CERTIFICATION ea022005201ex31-1_jasper.htm EX-31.1 11547
3 CERTIFICATION ea022005201ex31-2_jasper.htm EX-31.2 11100
4 CERTIFICATION ea022005201ex32-1_jasper.htm EX-32.1 7326
  Complete submission text file 0001213900-24-095173.txt   5295460

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE jspr-20240930.xsd EX-101.SCH 54419
6 XBRL CALCULATION FILE jspr-20240930_cal.xml EX-101.CAL 38043
7 XBRL DEFINITION FILE jspr-20240930_def.xml EX-101.DEF 255082
8 XBRL LABEL FILE jspr-20240930_lab.xml EX-101.LAB 460508
9 XBRL PRESENTATION FILE jspr-20240930_pre.xml EX-101.PRE 259849
76 EXTRACTED XBRL INSTANCE DOCUMENT ea0220052-10q_jasper_htm.xml XML 595596
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39138 | Film No.: 241433187
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)